Roche refuses to budge on price in face of snub from Illumina board
This article was originally published in Clinica
Executive Summary
In what looks likely to become a protracted affair, Illumina’s board of directors has unanimously rejected Roche’s $5.7bn hostile takeover attempt, as the latter continues to stick to its guns in terms of the offer price.